- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01708005
DIetary Supplements, Executive funcTions and Vitamin D (DIET-D) (DIET-D)
DIetary Supplements, Executive funcTions and Vitamin D (DIET-D): a Double-blind Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Current treatments for Alzheimer's disease (AD) are symptomatic and can only temporarily slow down AD without altering its natural evolution. The development of new therapies has primarily focused on preventing the progression of AD. This therapeutic strategy involves being interested in patients with an early stage of AD such as a mild cognitive impairment (MCI). We hypothesized that the combination of Lecitone®Se with 200 IU/day of vitamin D can slow or even improve cognitive decline, particularly executive functions.
The primary objective of this trial is to compare the effect after 12 weeks of the oral intake of Lecitone®Se-Vitamin D3 with the effect of a placebo on changes in performance obtained in the TMT B in the older adults with a MCI.
The secondary objectives of the study are as follows:
- To compare the effect after 12 weeks of the oral intake of Lecitone®Se-Vitamin D3 with the effect of a placebo on changes in executive performance in patients with a MCI.
- To compare the effect after 12 weeks of the oral intake of Lecitone®Se-Vitamin D3 with the effect of a placebo on changes in variability of stride time in patients with a MCI.
- To compare the effect after 24 weeks of the oral intake of Lecitone®Se-Vitamin D3 with the effect of a placebo and a delay phase of supplementation on changes in executive performance in patients with a MCI.
- To compare the effect after 24 weeks of the oral intake of Lecitone®Se-Vitamin D3 with the effect of a placebo and a delay phase of supplementation on changes in variability of stride time in patients with a MCI.
- To determine the compliance and tolerance of the oral intake of Lecitone®Se-Vitamin D3 in patients with a MCI.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Angers, France, 49933
- University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 60 years
- Memory complaints
- No dementia (DSM-IV, NINCDS-ADRDA negative)
- No depression (Geriatric Depression score ≤ 5/15)
- Ability to walk a distance of 15 meters unaided
- Diagnosis of MCI
- To have hypovitaminosis D (i.e. serum 25-hydroxyvitamin D [25OHD]concentration ≤ 30ng/mL)
- To have no hypercalcemia (defined as serum calcium concentration ≥ 2,65mmol/L)
- To have given and signed an informed consent to participate in the trial
- To be affiliated to French Social Security
Exclusion Criteria:
- Others cognitive disorders (untreated thyroid dysfunction, chronic ongoing ethylism, history of syphilis, stroke, severe depressive symptomatology (Geriatric Depression score > 5/15), existence of dementia according to DSM-IV and NINCDS-ADRDA criteria at the time of inclusion)
- Vitamin D supplementation during inclusion
- Contraindications to vitamin D
- Unstable medical condition
- Enrollment in another simultaneous clinical trial
- Civil defense measures underway
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Intervention
80 participants start the oral intake of Lecitone®Se-Vitamin D3 the day after inclusion and during 24 weeks
|
Lecitone®Se-Vitamin D3 is a dietary supplement combining the active ingredients in Lecitone®Se and 100 IU of vitamin D3. This dietary supplement comes in capsule form. Participants take 2 capsules of Lecitone®Se -Vitamin D3 per day. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study. |
Placebo Comparator: Placebo
80 participants in this arm start the oral intake of placebo the day after inclusion and during 12 weeks. Then, they start the oral intake of Lecitone®Se-Vitamin D3 12 weeks after inclusion until the 24th week. |
The comparator is represented by placebo capsules of identical appearance (same size, same color and same smell) that Lecitone®Se-Vitamin D3 capsules.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in executive performance
Time Frame: This outcome is assessed at baseline, 12 and 24 weeks after inclusion.
|
Executive performance is measured with Trial Making Test part B (TMT B)
|
This outcome is assessed at baseline, 12 and 24 weeks after inclusion.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in other executive scores
Time Frame: This outcome is assessed at baseline, 12 and 24 weeks after inclusion.
|
Test parts A and B, Stoop test, Processing Speed Index
|
This outcome is assessed at baseline, 12 and 24 weeks after inclusion.
|
Change in posture
Time Frame: This outcome is assessed at baseline, 12 and 24 weeks after inclusion.
|
Time Up & Go, Five Time Sit-to-Stand and spatio-temporal analysis of walking
|
This outcome is assessed at baseline, 12 and 24 weeks after inclusion.
|
Between-group comparison of compliance to treatment
Time Frame: This outcome is assessed at baseline, 12 and 24 weeks after inclusion.
|
This outcome is assessed together with the serum concentrations of 25OHD and calcium
|
This outcome is assessed at baseline, 12 and 24 weeks after inclusion.
|
Change in gait
Time Frame: This outcome is assessed at baseline, 12 and 24 weeks after inclusion
|
Time Up & Go, Five Time Sit-to-Stand and spatio-temporal analysis of walking
|
This outcome is assessed at baseline, 12 and 24 weeks after inclusion
|
Between-group comparison of tolerance
Time Frame: This outcome is assessed at baseline, 12 and 24 weeks after inclusion
|
This outcome is assessed with the serum concentrations of 25OHD and calcium
|
This outcome is assessed at baseline, 12 and 24 weeks after inclusion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Olivier Beauchet, MD,PhD, Angers University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012-A00453-40
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Cognitive Impairment
-
University of California, San FranciscoNational Institute on Aging (NIA)RecruitingMild Cognitive Impairment | Cognitive Decline | Cognitive Deterioration | Cognitive Impairment, Mild | Cognitive Deficits, MildUnited States
-
BaycrestCentre for Aging and Brain Health InnovationUnknownNeurocognitive Disorders | Cognitive Dysfunction | Mental Disorder | Cognitive Impairment, Mild | Cognitive Disorder | Nonamnestic Mild Cognitive ImpairmentCanada
-
Mackay Memorial HospitalBened Biomedical Co., Ltd.RecruitingMild Cognitive Impairment (MCI)Taiwan
-
Thomas Jefferson UniversityJohns Hopkins University; University of Pennsylvania; National Institute on Aging... and other collaboratorsCompletedMild Cognitive Impairment (MCI)United States
-
Palo Alto Veterans Institute for ResearchU.S. Army Medical Research and Development CommandCompletedAmnestic Mild Cognitive ImpairmentUnited States
-
Assaf-Harofeh Medical CenterNeurim Pharmaceuticals Ltd.UnknownMild Cognitive Impairment (MCI)Israel
-
Xuanwu Hospital, BeijingWuhan University; Beijing Friendship Hospital; First Affiliated Hospital Xi'an... and other collaboratorsRecruitingAmnestic Mild Cognitive ImpairmentChina
-
Immunotec Inc.RecruitingMild Cognitive Impairment (MCI)Canada
-
Jennifer BramenNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedAmnestic Mild Cognitive ImpairmentUnited States
-
Meir Medical CenterTerminatedMild Cognitive Impairment (MCI)Israel
Clinical Trials on Lecitone®Se-Vitamin D3
-
Aalborg UniversityAalborg University Hospital; CCBR Aalborg A/S, Aalborg, DenmarkCompletedMigraine According to International Headache Society (IHS) Criteria (ICHD-II)Denmark
-
Vadim Sherman, MDTexas Woman's University; The Methodist Hospital Research InstituteCompletedObesity | Vitamin D DeficiencyUnited States
-
Aga Khan UniversityCompletedVitamin D DeficiencyPakistan
-
Ludwig-Maximilians - University of MunichBayer; Roche Pharma AGActive, not recruiting
-
Medical University of ViennaUnknownVitamin D Deficiency | Kidney Transplantation | Renal OsteodystrophyAustria
-
Medical University of South CarolinaThrasher Research FundCompletedVitamin D Deficiency | PregnancyUnited States
-
Brigham and Women's HospitalNational Center for Maternal and Child Health Research, Mongolia; Zuun Kharaa...CompletedVitamin D Deficiency | PregnancyMongolia
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); Eunice Kennedy Shriver National Institute... and other collaboratorsCompletedHIV InfectionUnited States, Puerto Rico
-
Rutgers UniversityCompleted